Viela Bio A Randomized, Double-Blind, Multicenter,Placebo-Controlled Phase 3 Study With Open-Label Period To Evaluate The Efficacy And Safety Of Inebilizumab In Adults With Myasthenia Gravis
Posted Date: Mar 5, 2021
- Investigator: Hani Kushlaf
- Specialties:
- Type of Study: Drug
Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension
Criteria:
Adult Subjects Aged = 18 Years With Acetylcholine Receptor Antibody Positive (Achr-Ab+) Or Muscle-Specific Kinase-Antibody Positive (Musk-Ab+) Generalized Mg
Keywords:
Mg
For More Information:
Elizabeth Gehlmann
513-558-4497
gehlmaem@ucmail.uc.edu